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Abstract
Background: This study aimed to investigate renal outcomes and their predictors in biopsy-proven hypertensive
nephrosclerosis (HN) patients and to compare clinico-pathological characteristics and prognoses between benign
nephrosclerosis (BN) and malignant nephrosclerosis (MN) patients.
Methods: Data for biopsy-proven HN patients were retrospectively analyzed. Renal survival rates and relationships
between clinico-pathological characteristics and outcomes were assessed.
Results: A total of 194 patients were enrolled; the mean age at biopsy was 43.8 years, and male gender
predominated (82.5 %). The median duration of hypertension was 5.0 years, and the mean systolic and diastolic
blood pressures were 195 ± 37 and 126 ± 26 mmHg, respectively. The median serum creatinine (Scr) level, estimated
glomerular filtration rate (eGFR), and proteinuria level were 1.61 mg/dl, 49.6 ml/min/1.73 m2, and 0.80 g/24 h,
respectively. BN and MN were found by renal biopsy in 55.2 % and 44.8 % of patients, respectively. At biopsy, MN
patients were younger, and had higher median Scr and proteinuria levels, higher incidences of anemia,
hypertensive heart disease and hypertensive retinopathy, and worse renal outcomes than BN patients. During a
median follow-up period of 3.0 years, 36 patients (18.6 %) reached end-stage renal disease (ESRD), and the 5- and
10-year cumulative renal survival rates for HN patients were 84.5 % and 48.9 %, respectively. A decreased baseline
eGFR, an increased baseline proteinuria level, anemia, increased percentage of global glomerulosclerosis and
tubular atrophy and interstitial fibrosis (TAIF) were independent predictors of future ESRD.
Conclusions: The clinico-pathological characteristics and prognoses were significantly different between the MN
and BN patients. The renal outcomes of HN patients were independently associated with the baseline eGFR and
proteinuria level, anemia, percentage of global glomerulosclerosis and TAIF.
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Background
Hypertension is a worldwide public health challenge due
to its high prevalence, occurring in up to 26 % of the
adult population [1], and the concomitant risks of car-
diovascular, cerebrovascular and kidney disease. Hyper-
tensive nephrosclerosis (HN) is a common risk factor for
end-stage renal disease (ESRD) in developed countries,
accounting for 3.3-23.4 % of ESRD patients in Europe
(according to the ERA-EDTA Registry Annual Report,
2011) and 30.5 % of ESRD patients in the US [2]. The in-
cidence of ESRD is 2.7 per 100,000 person-years in the
Chinese population [3]; thus, it is a great burden in this
country because of the large population.
Usually, a diagnosis of HN is assigned based on clinical
manifestations. Most studies of HN have focused on the
clinical predictors of renal disease progression, including
race [4, 5], blood pressure [6–9], renal dysfunction
[elevated serum creatinine (Scr) level or decreased
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estimated glomerular filtration rate (eGFR)] [6, 10–13],
proteinuria [10, 11], and concomitant cardiovascular dis-
ease [11, 14, 15]. Hypertension is divided into benign
hypertension and malignant hypertension, and renal
damage from these types of hypertension is categorized
as benign nephrosclerosis (BN) and malignant nephro-
sclerosis (MN), respectively. Long-term renal outcomes
are much worse in patients with malignant hypertension
[16, 17] than in those with benign hypertension [4].
Renal biopsy is useful for the differential diagnosis be-
tween HN and primary glomerulonephritis with hyper-
tension [18–20], but only a limited number of studies of
biopsy-proven HN have focused on long-term renal out-
comes and negative prognostic factors [10–13, 21, 22].
We analyzed data from adult Chinese patients with
biopsy-proven HN to investigate the clinico-pathological
characteristics and to evaluate the long-term renal
survival rates and related risk factors for progression to
ESRD. In addition, the clinico-pathological characteris-




The clinical and renal histopathological data of patients
with biopsy-proven HN in Jinling Hospital, Nanjing,
from January 2003 to June 2013 were retrospectively
reviewed. During the study period, the total number of
native kidney biopsies was 31594, from which 411 pa-
tients (1.3 %) with a diagnosis of HN were identified.
The inclusion criteria were as follows: (1) evidence of
hypertension before the detection of proteinuria, hematuria
and/or impaired renal function; (2) evidence of HN on
renal histology; (3) the lack of any clinical, immunological
or histological evidence of other glomerular disease or
systemic disorder, such as glomerulonephritis or dia-
betic nephropathy, and the lack of any defined cause of
thrombotic microangiopathy such as hemolytic uremic
syndrome or thrombotic thrombocytopenic purpura;
(4) an age of between 18 and 65 years; (5) a follow-up
period of ≥1.0 year or reaching ESRD within 1 year;
and (6) the availability of adequate biopsies (≥8 glom-
eruli). A total of 194 patients were included in this
study.
Indications for renal biopsies included proteinuria
(>0.4 g/24 h), hematuria (urine sediment red cell count
>100,000 cells/ml) and/or impaired renal function. Renal
biopsies were performed after adequate blood pressure
control was achieved.
Clinical and laboratory parameters
The baseline and follow-up data of the patients were ob-
tained by retrospective chart review. The data included
gender, age, family history of hypertension, hypertension
duration, systolic blood pressure (SBP), diastolic blood
pressure (DBP), smoking status, Scr, and uric acid
levels, anemia (male: hemoglobin < 120 g/L, female:
hemoglobin < 110 g/L), elevated lactate dehydrogenase
(LDH) (LDH > 240 U/L), thrombocytopenia (platelets <
100 × 109/L), 24-h urinary protein excretion, micro-
scopic hematuria, hypertensive heart disease, cerebro-
vascular disease, and retinopathy (using the Keith-
Wagener-Barker criteria). The eGFR was calculated
using the Chronic Kidney Disease Epidemiology Collab-
oration (CKD-EPI) equation. Mean arterial pressure
(MAP) was defined as the diastolic pressure plus one
third of the pulse pressure. For each patient, the highest
blood pressure before biopsy and the time-average
blood pressure during follow-up, which was defined as
the ratio of the area under the curve of MAP during
follow-up to the duration of the follow-up [23], were re-
corded. The number of antihypertensive medications
taken during the follow-up period was collected, and oral
antihypertensive drugs were categorized into the following
classes: angiotensin-converting enzyme inhibitors (ACEIs)
and/or angiotensin receptor blockers (ARBs), calcium
channel blockers (CCBs), beta blockers (BBs), diuretics
and others. Patients were censored at the start of renal re-
placement therapy or loss to follow-up.
Renal histopathology
The tissue for light microscopy was serially sec-
tioned, using hematoxylin and eosin, periodic acid-
Schiff, methenamine-silver, and Masson trichrome
stains. Cryosections were stained with fluorescein
isothiocyanate-conjugated rabbit anti-human immuno-
globulin G (IgG), IgA, IgM, complement 3 (C3), and C1q.
Paraffin sections were stained with fibrinogen. The tissue
for electron microscopy was processed according to
standard protocols. All biopsy slides were re-reviewed by
two pathologists (Dr. Shaoshan Liang and Dr. Dandan
Liang) without knowledge of the clinical outcomes. A se-
nior pathologist (Dr. Caihong Zeng) reviewed the slides
and made the final decision in cases of disagreement.
HN was divided into two pathological patterns, BN
and MN. BN was characterized by arterial or arteriolar
hyalinosis, intimal fibrosis, or medial hypertrophy. MN
was characterized by fibrinoid necrosis (acute stage) or
myointimal cell proliferation, usually with an “onion-
skinning” appearance (chronic stage). Samples of con-
current MN and BN lesions were placed into the MN
group. The arteries and arterioles were semiquantita-
tively evaluated for hyalinosis on a scale of 0–2+ (0,
absent; 1+, present, nonocclusive of lumen; 2+, present,
extensive, and/or impinging on lumen); intimal fibrosis
on a scale of 0–4+ (0, no lesions; 1+, minimally
recognizable intimal fibrosis; 2+, intimal fibrosis with
<25 % luminal occlusion; 3+, intimal fibrosis with 26-50 %
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luminal occlusion; 4+, advanced lesions with >50 %
luminal occlusion); and medial hypertrophy on a scale of
0–2+ (0, absent; 1+, minimal to mild; 2+, moderate to
severe). The extents of global glomerulosclerosis, segmen-
tal glomerulosclerosis, and glomerular ischemia were
expressed as percentages of the total glomeruli. The mor-
phological classification of focal segmental glomerulo-
sclerosis (FSGS) was based on the Columbia classification
[24]. The severity of tubular atrophy and interstitial fibro-
sis (TAIF) was semiquantitatively scored as the percentage
of the renal cortical area involvement.
Outcome
The primary outcome of this study was ESRD, which
was defined as eGFR < 15 ml/min/1.73 m2, the initiation
of chronic renal replacement therapy, or transplantation.
Statistical analysis
Normally distributed variables were expressed as the
mean ± SD and compared using Student’s t-test. Non-
parametric variables were expressed as medians
[interquartile ranges (IQRs)] and compared using the
Mann–Whitney-Wilcoxon test. Categorical variables
were expressed as the number of positive cases (per-
centages) and compared using the Pearson χ2 test.
The reproducibility of the pathology variables was
evaluated using intraclass correlation coefficients
(ICCs). Correlations between the pathology variables
were analyzed using the Spearman test. The renal sur-
vival rates were estimated using the Kaplan-Meier
method, and the log-rank test was used to assess the
significance of differences in the Kaplan-Meier sur-
vival curves. The Cox proportional hazard model was
used to explore the influences of the variables on the
occurrence of ESRD. The pathological variables of
poor reproducibility (ICC <0.40) were excluded from
the model. The variables which were found to be sig-
nificant (P < 0.05) by univariate analysis were included
in the multivariate model using backward stepwise
method. The assumption of Cox proportional hazards
model were assessed using Schoenfeld residuals plots.
All P values were two-tailed, and a P < 0.05 was con-
sidered statistically significant. All analyses were per-
formed using SPSS 18.0 software for Windows (SPSS
Inc., Chicago, IL, USA) and R software (version 3.2.1).
Results
Clinical features
This study included 194 patients who were predomin-
antly male (82.5 %). The mean age at the time of biopsy
was 43.8 ± 4.1 years. The median duration of hyperten-
sion was 5.0 years (IQR, 1.0-9.0). The mean SBP and
DBP were 195 ± 37 and 126 ± 26 mmHg, respectively.
The median Scr level was 1.61 mg/dl (IQR, 1.24-2.27),
the median eGFR was 49.6 ml/min/1.73 m2 (IQR, 32.8-
65.7), and the median proteinuria level was 0.80 g/24 h
(IQR, 0.42-1.48). During a median follow-up period of
3.0 years (IQR, 1.8-4.3), 36 patients (18.6 %) developed
ESRD (Table 1), and the 5- and 10-year cumulative renal
survival rates after renal biopsy, calculated using Kaplan-
Meier method, were 84.5 % and 48.9 %, respectively
(Fig. 1). The average number of antihypertensive drugs
taken during the follow-up period was 2.7 ± 1.3; and
88.7 % of the patients were treated with ACEIs/ARBs,
75.8 % were treated with CCBs, 49.0 % were treated with
BBs, and 20.6 % were treated with diuretics.
Comparisons of clinical features between the MN and BN
groups
MN was found in 87 patients (44.8 %), and BN was
found in 107 (55.2 %). The comparisons of the clinical
features between the BN and MN groups are presented
in Table 1. The patients with MN were younger, had a
higher male: female ratio, had a shorter duration of
hypertension and had higher blood pressure. The MN
group had higher incidences of hypertensive heart dis-
ease and hypertensive retinopathy than the BN group.
The patients with MN exhibited more severe renal in-
juries, as indicated by higher median Scr, mean serum
uric acid and median proteinuria levels, and a higher in-
cidence of anemia, compared with those with BN.
Although the patients with MN received more antihy-
pertensive medications, the time-average MAP was
higher, and more patients progressed to ESRD than
those with BN (Table 1). The 5- and 10-year cumulative
renal survival rates after biopsy were 98.1 % and 58.3 %,
respectively, for the BN group, and 66.8 % and 19.4 %,
respectively, for the MN group (log-rank P < 0.001)
(Fig. 1).
Comparisons of histological features between the MN
and BN groups
The patients with MN exhibited more severe medial
hypertrophy, whereas those with BN exhibited a higher
hyalinosis score. The intimal fibrosis score was not sig-
nificantly different between the MN and BN groups. In
general, the percentage of segmental glomerulosclerosis
was significantly increased in the MN group compared
with the BN group. Ninety patients presented with seg-
mental glomerulosclerosis, 54 of which had the perihilar
variant. And the MN group had a higher incidence of
perihilar variant than the BN group (69.4 % vs. 48.8 %,
P = 0.047). The percentage of ischemic glomeruli was
significantly higher in the MN group than in the BN
group, but the percentage of global glomerulosclerosis
did not differ between two groups. The percentage of
TAIF was significantly greater in the MN group than in
the BN group (Table 2).
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Histological features of MN lesions
Of the 87 patients in the MN group, the incidence of ar-
teriolar involvement was 100 %, whereas that of arterial
involvement was 44.0 %. Chronic MN lesions were ob-
served in 94.3 % of the patients in the MN group with
arteriolar (81 cases) and arterial (37 cases) involvement.
Acute MN lesions were observed in 37.9 % of the
patients in the MN group with arteriolar (33 cases) and
arterial (1 case) involvement. Twenty-eight patients pre-
sented with both chronic and acute MN lesions. Only
one case showed glomerular fibrinoid necrosis.
Reproducibility was assessed statistically using ICCs,
which are summarized in Table 3.
Correlations between the pathology variables are
shown in Additional file 1: Table S1.
Clinical and pathological predictors of ESRD
Table 4 shows the MN lesions and renal outcomes for
the patients with preserved renal function vs. ESRD. The
patients with chronic and acute MN lesions had a higher
incidence of progression to ESRD than those with pre-
served renal function (77.8 % vs. 34.2 %, P < 0.001;
33.3 % vs. 13.3 %, P = 0.004, respectively). Based on the
vessel size, the involvement of both arterioles and arter-
ies in chronic MN lesions and the involvement of arteri-
oles in acute MN lesions were associated with ESRD.
The univariate Cox regression analysis indicated that
the baseline eGFR [hazard ratio (HR), 0.42, 95 % confi-
dence interval (CI), 0.32-0.56 per 10 ml/min/1.73 m2
increase, P < 0.001], baseline proteinuria (HR, 2.27, 95 %
CI, 1.70-3.02 per 1 g/24 h increase, P < 0.001), anemia








At time of biopsy
Sex (male:female) 160:34 81:26 79:8 0.006
Age (y) 43.8 ± 4.1 47.4 ± 10.3 39.4 ± 10.7 <0.001
Hypertension family history 114(58.8 %) 59(55.1 %) 55(63.2 %) 0.26
Hypertension duration (y) 5.0(1.0-9.0) 6.0(2.4-10.0) 3.0(0.2-7.0) <0.001
SBP (mmHg) 195 ± 37 182 ± 32 213 ± 32 <0.001
DBP (mmHg) 126 ± 26 119 ± 23 138 ± 25 <0.001
MAP (mmHg) 150 ± 27 139 ± 24 163 ± 25 <0.001
Current smoker 57(29.4 %) 30(28.0 %) 27(31.0 %) 0.65
Grades of retinopathy
I-II (%) (n*) 73(50.3 %)(145) 44(58.7 %)(75) 29(41.4 %)(70) <0.001
III-IV (%) (n*) 42(29.0 %)(145) 8(10.7 %)(75) 34(48.6 %)(70)
Hypertensive heart disease 110(56.7 %) 42(39.3 %) 68(78.2 %) <0.001
Hypertensive cerebrovascular disease 18(9.3 %) 12(11.2 %) 6(6.9 %) 0.30
Scr (mg/dl) 1.61(1.24-2.27) 1.35(1.07-1.60) 2.27(1.74-3.14) <0.001
eGFR (ml/min/1.73 m2) 49.6(32.8-65.7) 60.5(48.9-76.5) 34.5(24.2-46.8) <0.001
eGFR < 60 ml/min/1.73 m2 130(67.0 %) 51(47.7 %) 79(90.8 %) <0.001
Uric acid (μmol/l) 455 ± 109 437 ± 111 482 ± 101 0.004
Anemia 36(18.6 %) 10(9.3 %) 26(29.9 %) <0.001
Elevated LDH 5(2.6 %) 0(0 %) 5(5.7 %) -
Thrombocytopenia 1(0.5 %) 0(0 %) 1(1.1 %) -
Proteinuria (g/24 h) 0.80(0.42-1.48) 0.72(0.38-1.34) 0.89(0.58-1.57) 0.02
Microscopic hematuria 46(23.7 %) 31(29.0 %) 15(17.2 %) 0.06
Follow-up
No. of antihypertensive drugs 2.7 ± 1.3 2.3 ± 1.1 3.3 ± 1.2 <0.001
Time-average MAP (mmHg) (n*) 129 ± 13(157) 124 ± 11(88) 135 ± 14(69) <0.001
ESRD 36(18.6 %) 7(6.5 %) 29(33.3 %) <0.001
Data are presented as the medians (25th and 75th percentiles), the mean ± SD, or the number of positive cases (percentages). n* is the available n for a given
value. Where not specified, the available n is the same as the total number of cases in the top row
BN, benign nephrosclerosis; MN, malignant nephrosclerosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean blood pressure; Scr, serum
creatinine; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; ESRD, end-stage renal disease
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(HR, 4.18, 95 % CI, 2.10-8.33, P < 0.001), hyperuricemia
(HR, 2.31, 95 % CI, 1.08-4.93, P = 0.03), the percentage
of global glomerulosclerosis (HR, 1.44, 95 % CI, 1.23-
1.70 per 10 % increase, P < 0.001), percentage of segmen-
tal glomerulosclerosis (HR, 2.02, 95 % CI, 1.31-3.12 per
10 % increase, P = 0.001), percentage of TAIF (HR, 1.83,
95 % CI, 1.48-2.25 per 10 % increase, P < 0.001), and
the presence of MN (HR, 5.51, 95 % CI, 2.27-13.33,
P < 0.001) were associated with renal outcome (Table 5).
These parameters were then considered in the multivari-
ate Cox proportional hazards model, which showed that
the baseline eGFR (HR, 0.55, 95 % CI, 0.39-0.77 per
10 ml/min/1.73 m2 increase, P < 0.001), baseline pro-
teinuria (HR, 1.54, 95 % CI, 1.07-2.21 per 1 g/24 h
increase, P = 0.02), anemia (HR, 2.28, 95 % CI, 1.04-4.99,
P = 0.04), percentage of global glomerulosclerosis (HR,
1.33, 95 % CI, 1.12-1.58 per 10 % increase, P = 0.001) and
percentage of TAIF (HR, 1.48, 95 % CI, 1.08-2.03, P =
0.02) were independent predictors of renal outcome
(Table 6). Hyperuricemia, the percentage of segmental
glomerulosclerosis and the presence of MN were not pre-
dictive of renal outcome independently.
Discussion
The incidence of hypertension significantly increased
from 1991–2009 in China [25], and accordingly,
hypertension-induced renal damage also increased.
Based on the renal biopsy registry of Jinling Hospital,
Nanjing, the incidence of HN increased from 0.45 % in
1979–2002 [26] to 1.3 % in 2003–2013, which was simi-
lar to the findings of a recent report from Japan (1.3 %)
[27]. Therefore, HN might become a common risk factor
for ESRD in China.
Hypertension is categorized as benign hypertension
and malignant hypertension, and the renal damage
caused by these types of hypertension is classified as BN
Fig. 1 Kaplan-Meier renal survival curves for 194 patients with HN.
The 5- and 10-year cumulative renal survival rates after biopsy were
84.5 % and 48.9 %, respectively, for 194 patients with HN. The 5- and
10-year cumulative renal survival rates after biopsy were 98.1 % and
58.3 %, respectively, for the BN group, and 66.8 % and 19.4 %,
respectively, for the MN group (log-rank P < 0.001). HN,
hypertensive nephrosclerosis; BN, benign nephrosclerosis; MN,
malignant nephrosclerosis








Hyalinosis 1.09 ± 0.67 1.25 ± 0.57 0.90 ± 0.73 <0.001
Intimal fibrosis (n*) 1.74 ± 1.18(189) 1.79 ± 1.10(105) 1.68 ± 1.28(84) 0.52
Medial hypertrophy 0.69 ± 0.65 0.42 ± 0.55 1.01 ± 0.62 <0.001
Global glomerulosclerosis (%) 30(18–46) 32(18–45) 28(18–50) 0.63
Segmental glomerulosclerosis (%) 0(0–6) 0(0–5) 3(0–6) 0.04
Ischemic glomeruli (%) 8(0–22) 3(0–9) 20(8–30) <0.001
TAIF (%) 30(20–60) 30(10–30) 60(40–70) <0.001
Data are presented as the medians (25th and 75th percentiles), the mean ± SD. n* is the available n for a given value. Where not specified, the available n is the
same as the total number of cases in the top row
BN, benign nephrosclerosis; MN, malignant nephrosclerosis; TAIF, tubular atrophy/interstitial fibrosis
Table 3 ICCs of the HN patients
ICC
Acute MN lesions 0.66




Global glomerulosclerosis (%) 0.98
Segmental glomerulosclerosis (%) 0.94
Ischemic glomeruli (%) 0.71
TAIF (%) 0.75
Note: an ICC of less than 0.40 is poor reproducibility, 0.40-0.59 is reproducibility,
0.60-0.79 is substantial reproducibility, and 0.80-1 is outstanding reproducibility
MN, malignant nephrosclerosis; TAIF, tubular atrophy/interstitial fibrosis;
ICC: intraclass correlation coefficient
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and MN. MN was observed in 44.8 % of 194 patients
with biopsy-proven HN in the present study, which was
nearly identical to that reported by Caetano et al. (43 %)
[28] and was higher than those reported by other studies
(10.3-12.8 %) [20, 29]. The patients in our study were
Chinese, whereas those in the other studies were
Caucasian or African American. In Caetano’s study [28],
the average blood pressure was lower than that in the
present study (SBP/DBP 183/117 mmHg vs. 195/
126 mmHg), whereas the Scr level was higher (3.28 mg/
dl vs. 1.61 mg/dl). In Fogo’s study [20], the average eGFR
was higher than that in the present study (51.1 ml/min/
1.73 m2 vs. 49.6 ml/min/1.73 m2). The different inci-
dences of MN in biopsy-proven HN may be associated
with variations in ethnicity and patient inclusion criteria.
In the present study, the MN group was younger, dis-
played higher SBP and DBP levels, had higher median
Scr, mean uric acid and median proteinuria levels, and
had higher incidences of hypertensive heart disease and
retinopathy at baseline than the BN group. In Caetano’s
series [28], the MN group was younger, displayed higher
DBP and Scr levels, and had a higher incidence of
hypertensive retinopathy than the BN group, whereas
the uric acid and proteinuria levels were not different
between the two groups. In Bohle’s series [29], the MN
group was younger and displayed higher SBP and DBP,
and Scr and proteinuria levels than the BN group. In
Ratschek’s series [30], the MN group displayed higher
SBP and DBP and Scr levels, whereas no difference in
age was observed. Thus, the previous and present stud-
ies show that patients with MN are younger, have a
higher Scr level and a higher incidence of hypertensive
retinopathy, and have variable uric acid and proteinuria
levels compared with those with BN.
In the MN group, 5 patients had elevated LDH and 1
patient had thrombocytopenia at the time of biopsy. In
previous retrospective studies of patients with malignant
hypertension, 27-44 % of patients have presented with
thrombotic microangiopathy [16, 31, 32]. Microangio-
pathic hemolysis and thrombocytopenia have been re-
ported to resolve within 3–21.7 days and 3–5 days,
respectively, in patients with controlled blood pressure
[31, 33]. The low incidences of elevated LDH and
thrombocytopenia in this study may have been due to
the fact that the patients were receiving antihypertensive
therapies and had controlled blood pressure on admis-
sion to our hospital.
Two pathological patterns based on the vascular le-
sion, BN and MN, have been described as HN. MN is
characterized by fibrinoid necrosis (acute stage) and
myointimal cell proliferation, usually with an “onion-
skinning” appearance (chronic stage). In the present
study, the incidence of chronic-stage MN lesions was as
high as 94.3 % in the MN group, whereas that of acute-
stage MN lesions was low (37.9 % in the MN group).
Furthermore, most patients with acute-stage MN lesions
coexisted with chronic-stage MN lesions. These findings
are similar to those of previous reports [30, 34]. The
acute-stage MN lesions occurred during the more early
stage of severe hypertension [34]. All these patients had
to achieve adequate blood pressure control before biopsy
because of the potential hazard of bleeding complica-
tions. The low incidence of acute-stage lesions might
Table 4 MN lesions and renal outcomes for patients with
preserved renal function vs. ESRD
Preserved renal




MN 58(36.7 %) 29(80.6 %) <0.001
Chronic lesions 54(34.2 %) 28(77.8 %) <0.001
Arteriolar involvement 53(33.5 %) 28(77.8 %) <0.001
Arterial involvement (n*) 22(14.3 %)(154) 15(42.9 %)(35) <0.001
Acute lesions 21(13.3 %) 12(33.3 %) 0.004
Arteriolar involvement 21(13.3 %) 12(33.3 %) 0.004
Arterial involvement (n*) 0(0 %)(154) 1(2.9 %)(35) -
Data are presented as the number of positive cases (percentages). n* is the
available n for a given value. Where not specified, the available n is the same
as the total number of cases in the top row
MN, malignant nephrosclerosis; ESRD, end-stage renal disease
Table 5 Univariate Cox regression analyses of factors associated
with renal survival






Global glomerulosclerosisc 1.44(1.23-1.70) <0.001
Segmental glomerulosclerosisc 2.02(1.31-3.12) 0.001
Presence of MN 5.51(2.27-13.33) <0.001
aper 10 ml/min/1.73 m2 increase; bper 1 g/24 h increase; cper 10 % increase
MN, malignant nephrosclerosis; TAIF, tubular atrophy/interstitial fibrosis; HR,
hazard ratio; CI, confidence interval
Table 6 Multivariate Cox regression analyses of factors associated
with renal survival





Global glomerulosclerosisc 1.33(1.12-1.58) 0.001
aper 10 ml/min/1.73 m2 increase; bper 1 g/24 h increase; cper 10 % increase
TAIF, tubular atrophy/interstitial fibrosis; HR, hazard ratio; CI, confidence
interval
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have been due to the severe hypertension in the more
emergent patients serving as a contraindication of renal
biopsy. Segmental fibrinoid necrosis of the glomerular
tufts was perceived to be one of the characteristic lesions
associated with malignant hypertension [35]. Neverthe-
less, glomerular fibrinoid necrosis was found in only one
case in our study, and it was thus hard to evaluate its re-
lationship with malignant hypertension.
The patients with MN presented with more severe
histological lesions than those with BN. In agreement
with previous studies [29, 30], the MN group exhibited a
higher percentage of ischemic glomeruli (MN vs. BN,
20 % vs. 3 %). MN lesions led to marked narrowing or
even occlusion of the lumen and caused the formation
of ischemic glomeruli. Furthermore, the percentage of
segmental glomerulosclerosis in the MN group was
higher (MN vs. BN, 3 % vs. 0 %) and was predominantly
of the perihilar type. These data may reflect the fact that
the hyperfiltration status of the remaining nephron units
was more severe in the MN group than in BN group
[36]. The extent of TAIF was significantly higher in the
MN group in our study, and previous studies have dem-
onstrated that tubular atrophy and interstitial fibrosis
are associated with reduced flow in peritubular capillar-
ies, resulting in hypoxic damage [37, 38]. The MN le-
sions caused narrowing of the lumen and reduced renal
blood flow, leading to hypoxia and ultimately resulting
in TAIF. Thus, we speculated that the MN lesions
caused the devastating ischemic alterations that resulted
in ischemia of glomeruli, segmental glomerulosclerosis,
and TAIF. The MN group showed a higher medial
hypertrophy score than the BN group in the present
study, similar to the results of the study by Caetano [28].
Furthermore, our data showed that hyalinosis was more
frequent in the BN group than in the MN group.
HN can lead to ESRD, as shown in Table 7, which
summarizes the patient outcomes and prognostic indica-
tors in our study as well as those in previous reports. In
the present study, the 5- and 10-year cumulative renal
survival rates after biopsy were 98.1 % and 58.3 %, re-
spectively, for the BN group. The 5- and 10-year renal
survival rates of BN patients were respectively 80 % and
72 % in Norway [10], 56 % and 35 % in the UK [12], and
35.9 % and 23.6 % in Germany [13]. The patients in our
study were younger and had lower baseline Scr levels
than those in other studies. In addition, differences in
ethnicity and changes in treatment strategies in recent
decades might have contributed to the better renal out-
comes observed in our study compared with previous
studies. With the development of modern antihyperten-
sive drugs, the prognosis of clinical malignant hyperten-
sion has improved. We reported the long-term renal
outcome of biopsy-proven MN In this study, showing
that during a median follow-up period of 3.0 years,
33.3 % of the patients progressed to ESRD in the MN
group. Yu et al. reported that a series of MN patients, in
which more severe renal involvement was observed, had
a worse renal outcome (45.9 % patients progressed to
ESRD) during a mean follow-up period of 2.5 years than
the present study [39] (Table 7).
The clinical parameters showed significant prognostic
value for patients with HN. Our study confirmed the
baseline eGFR and proteinuria level as independent
prognostic factors for progression to ESRD [10–13, 40].
In addition, anemia was found to be an independent
prognostic factor for renal outcome. The serum uric acid
level was higher in the MN group than in the BN group
in our study. However, the presence of hyperuricemia,
which predicted outcome in univariate Cox analysis, lost
its prognostic value in multivariate Cox analysis. In the
African American Study of Kidney Disease (AASK) co-
hort [11], the baseline hematocrit level was significantly
associated with the risk for a GFR event or ESRD after
adjustments for age, gender, baseline proteinuria, and
baseline GFR, whereas no association was observed be-
tween serum uric acid level and renal outcome, which
was similar to the findings of our study. Further pro-
spective studies are required to confirm whether hyper-
uricemia is associated with renal outcomes for patients
with HN in the Chinese population. Several studies have
indicated that an increase in baseline blood pressure
[7, 8], treatment-resistant hypertension [6, 9], and in-
creases in SBP and DBP during follow-up [12, 16] are
associated with an unfavorable outcome. In the
present study, baseline blood pressure was not associated
with renal outcome; however, these data are limited by the
retrospective nature of this study. Prospective studies are
needed to confirm the optimal blood pressure control
strategy for patients with HN. Additionally, several studies
have indicated that concomitant cardiovascular disease is
associated with renal outcome [11, 14, 15]; however, no
such associations were observed in the current series of
patients.
Some pathological parameters were identified to pre-
dict renal outcome. TAIF was one of the prognostic fac-
tors identified in the present study that has also been
reported as a factor for other renal diseases [41]. Global
glomerulosclerosis also exhibited a significant negative
prognostic influence in our study. Interestingly, the opti-
mal cutoff of the percentage of global glomerulosclerosis
for predicting renal outcome obtained by receiver oper-
ating characteristic (ROC) curve analysis was 40 % (data
not shown), which was nearly the same as the value
obtained from a series of patients with biopsy-proven
BN in Japan, in which global glomerulosclerosis (>41 %)
at biopsy was found to be an indicator of poor prognosis
[21]. These findings suggest that global glomerulosclero-
sis has a negative prognostic impact on patients with
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Table 7 Renal outcomes and prognostic indicators for patients with biopsy-proven HN in the present study and in previous reports
Case numbers Sex (male:female) Age (y) Scr (eGFR) Proteinuria
(g/24 h)
BP (mmHg) Duration of
follow-up (y)
Renal outcomes Predictors of renal survival
Takebayashi [21] 590 2.5:1 56.5 1.90(ND) ND 154(SBP)87(DBP) 10.1 49.2 % of 345 cases reached
endpoint event (Scr ≥3 mg/dl)





Marcantoni [22] 62a 1.3:1 58.7 3.40(ND) 1.8 105 ± 3(MAP) 1.9 47.8 % of 23 cases reached
ESRD
ND
Wehrmann [13] 170 5.0:1 ND ND ND ND ND 5- and 10-year renal survival
rates were 35.9 % and 23.6 %,
respectively
Baseline Scr
Vikse [10] 102 2.0:1 55.4 1.87(ND) 0.4 156 ± 28(SBP);
92 ± 14(DBP)
11.7 5- and 10-year renal survival
rates were 80 % and 72 %,
respectively
Baseline Scr, proteinuria
Norris [11] 1094a 1.6:1 54.6 ND(46.4) 0.3 150 ± 24(SBP);
96 ± 14(DBP)
3.9 13.1 % reached endpoint event
(50 % or 25 ml/min per 1.73 m2
decline in GFR or ESRD)
Baseline proteinuria, GFR, Scr,urea
nitrogen, phosphorus
Dasgupta [12] 60 2.0:1 58.0 2.79(36.0) 2.3 179 ± 25(SBP);
105 ± 15(DBP)
6.7 5- and 10-year renal survival
rates were 56 % and 35 %,
respectively
Baseline Scr, mean SBP and DBP
during follow-up (univariate
analysis), DBP during follow-up
(multivariate analysis)
Yu [39] 61 9.2:1 32.0 6.33(ND) 3.46 ND 2.5 45.9 % reached ESRD ND
This study 194 4.7:1 43.8 1.61(49.6) 0.80 195 ± 37(SBP);
126 ± 26(DBP)
3.0 5- and 10-year renal survival
rates were 84.5 and 48.9 %,
respectively
Baseline eGFR, proteinuria,
anemia, the percentage of global
glomerulosclerosis and TAIF
aMost cases underwent renal biopsies
ND, no data; BP, blood pressure; MAP, mean blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MN, malignant nephrosclerosis; Scr, serum creatinine; eGFR, estimated glomerular filtration rate;












both BN and MN. Correlation analysis of pathology vari-
ables demonstrated that there was a strong correlation
between the presence of MN and the percentage of TAIF
(r = 0.643). Thus, the presence of MN predicted the risk
for progression to ESRD in univariate Cox analysis, but
lost its prognostic value in multivariate Cox analysis.
The limitations of this study must be recognized. The
major limitation in this study is its retrospective nature.
We cannot rule out the influence of selection bias be-
cause some patients, especially those only very mild
cases, were unwilling to undergo renal biopsy when HN
was diagnosed according to the clinical criteria. In
addition, data on patient deaths were incomplete and
the candidate factors associated with death were not
assessed in this study.
Conclusions
Our results indicated that patients with MN and BN
exhibited significantly different clinico-pathological char-
acteristics. The MN group presented with more severe
renal involvement and higher incidences of hypertensive
heart disease and retinopathy, received more antihyper-
tensive medications, and had poorer renal outcomes
than the BN group. A decreased baseline eGFR, an in-
creased baseline proteinuria level, anemia, increased per-
centage of global glomerulosclerosis and TAIF were
associated with unfavorable renal outcomes in the pa-
tients with biopsy-proven HN.
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